IPMN-carcinoma (intraductal papillary mucinous neoplasms) – invasive intraductal papillary mucinous pancreatic cancer-a malignant tumor that occurs against the background of an existing intraductal papillary mucinous tumor as a result of its malignancy (malignancy).

Who is at risk?

The main risk factor is the presence of a cystic pancreatic tumor (IPMN). Malignancy occurs more often in the elderly, in patients over 65 years of age. Men get sick more often. In addition, smoking, alcohol intake, and the presence of chronic pancreatitis are risk factors for the development of the disease.

You can suspect the disease if the following symptoms occur:

  • pain in the upper abdomen,
  • yellowing of the skin (mechanical jaundice),
  • nausea,
  • vomiting,
  • weight loss,
  • the presence of an admixture of mucus in the feces.

If any of these signs appear, you should consult a doctor. You can not engage in any self-medication, as these symptoms can be the result of a large number of other diseases. The specialist will assess the situation and prescribe the necessary examination.

The following methods are used to diagnose IPMN-carcinoma.

First of all, the so-called non-invasive methods, when the examination is carried out without one or another penetration into the body and there are practically no complications

  • Ultrasound examination of the abdominal organs.
  • Computed tomography (CT) of the abdominal cavity with intravenous contrast.
  • Magnetic resonance imaging (MRI) of the abdominal cavity, including in the mode of magnetic resonance cholangiopancreaticography (MRCP).

Invasive (with penetration into the body) methods include endosonography (ultrasound through an endoscope) with a possible biopsy.

Among the laboratory parameters, in addition to the biochemical ones, the data of the tumor markers CEA and CA19-9 are important. They have not only diagnostic, but also prognostic value.

The survey data, combined with clinical data and taking into account the general condition of the patient, allow us to determine a rational treatment strategy.

In the Moscow Clinical Scientific and Practical Center named after A. S. Loginov, this issue is resolved in each specific case at a consultation (meeting) of all necessary specialists, primarily oncologists and surgeons.

In some cases, surgical treatment with/without subsequent chemotherapy is indicated at the first stage. In our center, modern laparoscopic operations are performed, including with the use of the DaVinci robot. We have accumulated the largest experience in Russia and one of the largest in the world of laparoscopic operations on the pancreas.

In other cases, treatment begins with chemotherapy, and then, depending on its results, the question of surgery is discussed again. Currently, the Center employs a team of leading oncologists in Russia, who have the necessary modern means of treatment.

Do not delay your visit to the specialists of our Center. This will help to diagnose the disease in a timely manner and choose the right treatment tactics. Doctors of the Department of High-tech Surgery and Surgical Endoscopy and the Department of Chemotherapy of the State Medical Institution of the Moscow State Medical Center named after A. S. Loginov DZM are always ready to help you. 

GBUZ Moscow Clinical Scientific Center named after Loginov MHD